Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma

Urothelial carcinoma (UC) occupies a high incidence among all the genitourinary malignancies. Immune checkpoint inhibitors (ICIs), as alternative treatments of metastatic urothelial carcinoma (mUC), have been applied in the treatment of mUC after chemotherapy failure, with comparable efficacy and sa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Di Wang, Kai Sun, Tianqi Wang, Dongxu Zhang, Fengze Sun, Yuanshan Cui, Hongwei Zhao, Jitao Wu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	urothelial carcinoma (UC) immune checkpoint inhibitor (ICI) immune-related adverse events (irAEs) programmed cell death protein 1 (PD1) programmed cell death ligand protein 1 (PD-L1) Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/6f20daceeec04829aec04e89e2005d36
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6f20daceeec04829aec04e89e2005d36
record_format	dspace
spelling	oai:doaj.org-article:6f20daceeec04829aec04e89e2005d362021-11-12T04:49:15ZAdverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma1663-981210.3389/fphar.2021.710943https://doaj.org/article/6f20daceeec04829aec04e89e2005d362021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.710943/fullhttps://doaj.org/toc/1663-9812Urothelial carcinoma (UC) occupies a high incidence among all the genitourinary malignancies. Immune checkpoint inhibitors (ICIs), as alternative treatments of metastatic urothelial carcinoma (mUC), have been applied in the treatment of mUC after chemotherapy failure, with comparable efficacy and safety. ICIs can enhance anti-tumor T cell reactivity and promote immune control over the cancerous cells by blocking cytotoxic T-lymphocyte antigen 4 (CTLA-4) or the combination of PD-1 and PD-L1. In the treatment of urothelial carcinoma, ICIs show obvious advantage and can enhance survival rates. However, their adverse effects are gradually manifested with increasing clinical applications. Therefore, we review the adverse effects and toxicity of ICIs in patients with UC, aiming to provide sound theoretical references and therapeutic strategies for their clinical application.Di WangKai SunTianqi WangDongxu ZhangFengze SunYuanshan CuiHongwei ZhaoJitao WuFrontiers Media S.A.articleurothelial carcinoma (UC)immune checkpoint inhibitor (ICI)immune-related adverse events (irAEs)programmed cell death protein 1 (PD1)programmed cell death ligand protein 1 (PD-L1)Therapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	urothelial carcinoma (UC) immune checkpoint inhibitor (ICI) immune-related adverse events (irAEs) programmed cell death protein 1 (PD1) programmed cell death ligand protein 1 (PD-L1) Therapeutics. Pharmacology RM1-950
spellingShingle	urothelial carcinoma (UC) immune checkpoint inhibitor (ICI) immune-related adverse events (irAEs) programmed cell death protein 1 (PD1) programmed cell death ligand protein 1 (PD-L1) Therapeutics. Pharmacology RM1-950 Di Wang Kai Sun Tianqi Wang Dongxu Zhang Fengze Sun Yuanshan Cui Hongwei Zhao Jitao Wu Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
description	Urothelial carcinoma (UC) occupies a high incidence among all the genitourinary malignancies. Immune checkpoint inhibitors (ICIs), as alternative treatments of metastatic urothelial carcinoma (mUC), have been applied in the treatment of mUC after chemotherapy failure, with comparable efficacy and safety. ICIs can enhance anti-tumor T cell reactivity and promote immune control over the cancerous cells by blocking cytotoxic T-lymphocyte antigen 4 (CTLA-4) or the combination of PD-1 and PD-L1. In the treatment of urothelial carcinoma, ICIs show obvious advantage and can enhance survival rates. However, their adverse effects are gradually manifested with increasing clinical applications. Therefore, we review the adverse effects and toxicity of ICIs in patients with UC, aiming to provide sound theoretical references and therapeutic strategies for their clinical application.
format	article
author	Di Wang Kai Sun Tianqi Wang Dongxu Zhang Fengze Sun Yuanshan Cui Hongwei Zhao Jitao Wu
author_facet	Di Wang Kai Sun Tianqi Wang Dongxu Zhang Fengze Sun Yuanshan Cui Hongwei Zhao Jitao Wu
author_sort	Di Wang
title	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
title_short	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
title_full	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
title_fullStr	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
title_full_unstemmed	Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
title_sort	adverse effects and toxicity of immune checkpoint inhibitors for patients with urothelial carcinoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/6f20daceeec04829aec04e89e2005d36
work_keys_str_mv	AT diwang adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT kaisun adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT tianqiwang adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT dongxuzhang adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT fengzesun adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT yuanshancui adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT hongweizhao adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma AT jitaowu adverseeffectsandtoxicityofimmunecheckpointinhibitorsforpatientswithurothelialcarcinoma
_version_	1718431176291516416

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma

Ejemplares similares